Theseus Pharmaceuticals, Inc. (THRX)

Theseus Pharmaceuticals Income Statement

Financials in millions USD. Fiscal year is January - December.

Year Ending	TTM	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Selling, General & Admin	19.3	18.39	9.01	0.88	0.82
Research & Development	47.22	35.7	18.33	5.96	4.12
Operating Expenses	66.52	54.09	27.34	6.84	4.94
Operating Income	-66.52	-54.09	-27.34	-6.84	-4.94
Other Expense / Income	-9.91	-3.48	-0.03	5.16	2.24
Pretax Income	-56.61	-50.61	-27.31	-12	-7.18
Net Income	-56.61	-50.61	-27.31	-12	-7.18
Shares Outstanding (Basic)	44	38	10	1	0
Shares Outstanding (Diluted)	44	38	10	1	0
Shares Change	13.52%	299.61%	1594.35%	257.58%	-
EPS (Basic)	-1.34	-1.31	-2.84	-21.10	-45.18
EPS (Diluted)	-1.34	-1.31	-2.84	-21.10	-45.18
Free Cash Flow	-49.7	-33.4	-27.19	-4.85	-4.81
Free Cash Flow Per Share	-1.14	-0.87	-2.82	-8.54	-30.24
EBITDA	-55.98	-50.17	-27.31	-12	-7.18
Depreciation & Amortization	0.63	0.44	0	0	0
EBIT	-56.61	-50.61	-27.31	-12	-7.18

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).